Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaluating Cardlytics’ blend of purchase-based advertising, bank-rewards economics, and Bridg subscription revenue means navigating dense SEC language. Reports often run over 200 pages and scatter critical metrics—active financial-institution users, cost-per-served-impression, and segment margins—across exhibits. If you have searched “Cardlytics quarterly earnings report 10-Q filing” or wondered how to track “Cardlytics insider trading Form 4 transactions,” this page eliminates the chase.
Stock Titan’s AI-powered analysis delivers answers the instant a document posts to EDGAR. For investors looking for “Cardlytics SEC filings explained simply,” our engine creates plain-English summaries, redlines new risk factors, and auto-builds valuation tables, so understanding Cardlytics SEC documents with AI takes minutes, not hours. Real-time alerts flag “Cardlytics Form 4 insider transactions real-time,” while side-by-side comparisons present a “Cardlytics annual report 10-K simplified” without diluting nuance.
Practical workflows matter: monitor “Cardlytics executive stock transactions Form 4” before earnings, compare loyalty-program economics via the latest “Cardlytics earnings report filing analysis,” or review governance details inside the “Cardlytics proxy statement executive compensation” section. Need to confirm a sudden partnership? Find the “Cardlytics 8-K material events explained” entry in seconds. With complete coverage of every form type, AI-driven summaries, and timely notifications, you gain the clarity required to act on CDLX disclosures while others are still downloading PDFs.
Cardlytics, Inc. (CDLX) – Form 4 insider transaction filing
On 06/23/2025 the company granted its Chief Financial Officer, Alexis DeSieno, 40,000 restricted stock units (RSUs) and 15,000 performance stock units (PSUs). The awards were reported under transaction code “A” (grant) and carry a $0 exercise price, meaning they are issued at no cash cost to the executive.
The RSUs vest 50 % on 06/23/2026; the remaining 50 % vests in equal quarterly installments through 06/23/2027, subject to continued employment. The PSUs vest in specified percentages once undisclosed share-price hurdles are met, also contingent on employment. Following the grant, DeSieno beneficially owns 40,000 RSUs and 15,000 PSUs, all held directly.
Because the filing reflects equity compensation rather than an open-market purchase or sale, it does not alter immediate cash flows or signal a directional view on the stock. Nonetheless, the multi-year, performance-linked structure strengthens management alignment with long-term shareholder value while introducing potential future dilution of up to 55,000 shares.
Cardlytics, Inc. (CDLX) – Form 4 insider filing dated 06/25/2025 details an equity award to Chief Legal & Privacy Officer Nicholas Hollmeyer Lynton.
Derivative securities granted:
- 25,000 Restricted Stock Units (RSUs) awarded on 06/23/2025. The grant carries no exercise price.
- 9,375 Performance Stock Units (PSUs) awarded on the same date, also at a zero cost basis.
Vesting terms:
- RSUs – 50 % vest on 06/23/2026; the balance vests in equal quarterly instalments through 06/23/2027, contingent upon continued employment.
- PSUs – Vest in specified brackets only upon achievement of undisclosed share-price targets, and require continued employment on the applicable vesting dates.
Post-transaction ownership: The officer now directly holds 25,000 RSUs and 9,375 PSUs, each convertible into one share of common stock upon vesting, giving potential ownership of 34,375 additional common shares.
Key takeaways for investors: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale; therefore, it does not immediately alter the company’s share count or insider ownership percentages. The inclusion of PSUs tied to price targets signals performance alignment between the executive and shareholders, but the ultimate dilution impact will depend on future vesting and share-price performance.
FAQ
What is the current stock price of Cardlytics (CDLX)?
What is the market cap of Cardlytics (CDLX)?
